查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1596234

视网膜病变治疗药物市场：按类型、剂型、分销管道划分 - 全球预测 2025-2030

Retinal Disorder Treatment Market by Type (Diabetic Retinopathy, Macular Degeneration), Dosage Form (Capsules & Tablets, Eye Drops, Eye Solutions), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年视网膜病变治疗市值为86.2亿美元，预计2024年将达到93.8亿美元，复合年增长率为8.94%，到2030年将达到157亿美元。

视网膜病变药物市场包括旨在控制影响视网膜的疾病的各种治疗策略，例如老龄化黄斑部病变、糖尿病视网膜病变和视网膜剥离。由于人口老化以及糖尿病和高血压盛行率上升，需要这些治疗。治疗方法包括抗 VEGF 注射、雷射治疗和手术介入等药物治疗。应用范围广泛，针对医院、眼科诊所、研究所等医疗环境。该市场预计将成长，特别是随着基因治疗和干细胞研究技术的进步并提供有前景的解决方案和成果。关键的成长要素包括老年人口的成长、技术的进步以及医疗保健提供者对早期疗育的认识的提高。潜在的机会在于远端医疗服务以及预测分析和个人化医疗的人工智慧整合。公司可以透过投资研发、利用巨量资料分析和建立策略伙伴关係来利用这些优势。然而，治疗成本上升、监管障碍以及欠发达地区的准入有限等限制因素。此外，新兴市场缺乏熟练的眼科医生和医疗基础设施不足等挑战也可能阻碍成长。市场竞争仍然激烈，需要持续创新，重点是改进具有成本效益的治疗解决方案和配方。需要创新的领域包括开发非侵入性治疗方法和增强输送系统以提高患者的依从性。该市场的特点是快速的技术适应导致治疗模式的重大转变。为了取得成功，公司必须保持敏捷，优先考虑跨部门协作，并维持强大的新产品开发管道。总体而言，使策略性倡议与新兴趋势保持一致对于维持市场相关性并实现视网膜病变治疗领域的业务成长至关重要。

主要市场统计
基准年[2023] 86.2亿美元
预测年份 [2024] 93.8亿美元
预测年份 [2030] 157亿美元
复合年增长率（%） 8.94%

市场动态：快速发展的视网膜病变治疗市场的关键市场洞察

供需的动态交互作用正在改变视网膜病变药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 监管机构增加对眼科疾病研究的资助
    • 全球视网膜疾病盛行率不断上升
    • 黄斑部病变导致老年人口增加
  • 市场限制因素
    • 研发成本高
  • 市场机会
    • 治疗方面的创新与进步
    • 扩大策略联盟并将新产品商业化
  • 市场挑战
    • 可能出现眼部併发症

波特五力：驾驭视网膜疾病药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解视网膜病变治疗药物市场的外部影响

外部宏观环境因素在塑造视网膜疾病治疗药物市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解视网膜疾病治疗药物市场的竞争状况

对视网膜病变治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵视网膜病变治疗市场供应商的绩效评估

FPNV 定位矩阵是评估视网膜病变治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘视网膜病变治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，视网膜病变治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 眼科疾病研究的监管经费增加
      • 全球视网膜疾病的盛行率正在增加
      • 老年人口增加和黄斑部病变
    • 抑制因素
      • 研发活动成本高
    • 机会
      • 技术创新和治疗方法进步
      • 扩大策略合作并将新产品商业化
    • 任务
      • 可能出现眼部併发症
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章视网膜病变治疗药物市场：依类型

  • 糖尿病视网膜病变
  • 黄斑部病变
    • 干性黄斑部病变
    • 湿性黄斑部病变

第七章依剂型分類的视网膜病变治疗药物市场

  • 胶囊和片剂
  • 眼药水
  • 眼液
  • 凝胶
  • 软膏

第八章视网膜病变治疗药物市场：依分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章北美和南美视网膜疾病治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太视网膜病变治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第11章：欧洲、中东和非洲视网膜病变治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Abeona Therapeutics Inc.
  • Apellis Pharmaceuticals, Inc.
  • Bausch & Lomb Incorporated
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Graybug Vision Inc.
  • Kubota Pharmaceutical Holdings Co., Ltd.
  • Novartis AG
  • ONL Therapeutics
  • Opthea
  • Oxford Biomedica PLC
  • Oxurion NV
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Spark Therapeutics, Inc.
Product Code: MRR-CA17E905E6E9

The Retinal Disorder Treatment Market was valued at USD 8.62 billion in 2023, expected to reach USD 9.38 billion in 2024, and is projected to grow at a CAGR of 8.94%, to USD 15.70 billion by 2030.

The retinal disorder treatment market encompasses a range of therapeutic strategies aimed at managing conditions affecting the retina, such as age-related macular degeneration, diabetic retinopathy, and retinal detachment. The necessity for these treatments stems from the increasing prevalence of these disorders, largely driven by an aging population and rising incidence of diabetes and hypertension. Treatments include pharmacologic therapies, such as anti-VEGF injections, laser treatments, and surgical interventions. The application scope is broad, targeting healthcare settings like hospitals, ophthalmology clinics, and research institutes. The market is poised for growth due to advancing technologies, particularly in gene therapy and stem cell research, offering promising solutions and outcomes. Key growth influencers include the rising geriatric population, technological advancements, and increased awareness among healthcare providers regarding early intervention. Potential lucrative opportunities lie in telemedicine services and the integration of AI for predictive analytics and personalized medicine. Companies can capitalize on these by investing in research and development, leveraging big data analytics, and forming strategic partnerships. However, limitations include high treatment costs, regulatory hurdles, and limited access in underdeveloped regions. Additionally, challenges such as a shortage of skilled ophthalmologists and insufficient healthcare infrastructure in emerging markets could impede growth. The market remains highly competitive with a need for continuous innovation, demanding a focus on cost-effective therapeutic solutions and improved drug formulations. Areas ripe for innovation include developing non-invasive treatment methodologies and enhanced delivery systems to improve patient compliance. The market is nature-driven by rapid technological adaptation, leading to substantial shifts in treatment paradigms. Successful navigation requires companies to remain agile, prioritize cross-sector collaborations, and maintain robust pipelines for new product development. Overall, aligning strategic initiatives with emerging trends will be vital for sustaining market relevance and achieving business growth in the retinal disorder treatment domain.

KEY MARKET STATISTICS
Base Year [2023] USD 8.62 billion
Estimated Year [2024] USD 9.38 billion
Forecast Year [2030] USD 15.70 billion
CAGR (%) 8.94%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Retinal Disorder Treatment Market

The Retinal Disorder Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing funding by regulatory bodies for research on ocular disorders
    • Increasing prevalence of retinal disorders globally
    • Rising elderly population coupled with macular degeneration
  • Market Restraints
    • High cost involved in research and development activities
  • Market Opportunities
    • Technological innovations and advancements in treatments
    • Growing strategic collaborations and commercialization of novel products
  • Market Challenges
    • Probable complications in the eye

Porter's Five Forces: A Strategic Tool for Navigating the Retinal Disorder Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Retinal Disorder Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Retinal Disorder Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Retinal Disorder Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Retinal Disorder Treatment Market

A detailed market share analysis in the Retinal Disorder Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Retinal Disorder Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Retinal Disorder Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Retinal Disorder Treatment Market

A strategic analysis of the Retinal Disorder Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Retinal Disorder Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Abeona Therapeutics Inc., Apellis Pharmaceuticals, Inc., Bausch & Lomb Incorporated, Bayer AG, F. Hoffmann-La Roche Ltd., Graybug Vision Inc., Kubota Pharmaceutical Holdings Co., Ltd., Novartis AG, ONL Therapeutics, Opthea, Oxford Biomedica PLC, Oxurion NV, Pfizer, Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co., Ltd., and Spark Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Retinal Disorder Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Diabetic Retinopathy and Macular Degeneration. The Macular Degeneration is further studied across Dry Macular Degeneration and Wet Macular Degeneration.
  • Based on Dosage Form, market is studied across Capsules & Tablets, Eye Drops, Eye Solutions, Gels, and Ointments.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing funding by regulatory bodies for research on ocular disorders
      • 5.1.1.2. Increasing prevalence of retinal disorders globally
      • 5.1.1.3. Rising elderly population coupled with macular degeneration
    • 5.1.2. Restraints
      • 5.1.2.1. High cost involved in research and development activities
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological innovations and advancements in treatments
      • 5.1.3.2. Growing strategic collaborations and commercialization of novel products
    • 5.1.4. Challenges
      • 5.1.4.1. Probable complications in the eye
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Retinal Disorder Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Diabetic Retinopathy
  • 6.3. Macular Degeneration
    • 6.3.1. Dry Macular Degeneration
    • 6.3.2. Wet Macular Degeneration

7. Retinal Disorder Treatment Market, by Dosage Form

  • 7.1. Introduction
  • 7.2. Capsules & Tablets
  • 7.3. Eye Drops
  • 7.4. Eye Solutions
  • 7.5. Gels
  • 7.6. Ointments

8. Retinal Disorder Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Americas Retinal Disorder Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Retinal Disorder Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Retinal Disorder Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Abeona Therapeutics Inc.
  • 3. Apellis Pharmaceuticals, Inc.
  • 4. Bausch & Lomb Incorporated
  • 5. Bayer AG
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. Graybug Vision Inc.
  • 8. Kubota Pharmaceutical Holdings Co., Ltd.
  • 9. Novartis AG
  • 10. ONL Therapeutics
  • 11. Opthea
  • 12. Oxford Biomedica PLC
  • 13. Oxurion NV
  • 14. Pfizer, Inc.
  • 15. Regeneron Pharmaceuticals Inc.
  • 16. Santen Pharmaceutical Co., Ltd.
  • 17. Spark Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. RETINAL DISORDER TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. RETINAL DISORDER TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. RETINAL DISORDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. RETINAL DISORDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RETINAL DISORDER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RETINAL DISORDER TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRY MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY WET MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CAPSULES & TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY EYE SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. RETINAL DISORDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. RETINAL DISORDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023